Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
Sterilized wound healing compositions comprise stabilized cyanoacrylate monomers homogenously mixed together with a naphthoquinone 2,3-oxide, including vitamin K oxides. The compositions are sterilized by irradiation, and the sterilized compositions are shelf stable such that their viscosity does not substantially increase following at least two years of shelf storage. The compositions may be used for closure of open wounds, and the compositions enhance the rate of wound healing relative to wounds not closed with the compositions.
1. A sterilized cyanoacrylate composition, comprising:
about 90% to about 98% by weight of a cyanoacrylate monomer,
about 200 ppm to about 16,000 ppm of a free radical stabilizer,
at least about 20 ppm of an anionic stabilizer,
about 2% to about 10% by weight of a naphthoquinone 2,3- oxide of Formula (III)
wherein R 1 is an alkyl group or an aromatic group, and R 2 is hydrogen, an alkyl group, or an aromatic group, and
optionally about 10 ppm to about 6000 ppm of a polymerization accelerator, wherein the naphthoquinone 2,3- oxide is miscible with and homogenously mixed together with the cyanoacrylate monomer, wherein the composition is sterilized by ethylene oxide, irradiation, or both ethylene oxide and irradiation, and wherein the viscosity of the sterilized composition is no more than about 200 centipoise after at least two years of shelf storage.
2. The composition of claim 1 , wherein the cyanoacrylate monomer is 2-octyl cyanoacrylate, n-butyl cyanoacrylate, or mixtures thereof.
3. The composition of claim 1 , wherein the free radical stabilizer is butylated hydroxyl anisole.
4. The composition of claim 1 , wherein the anionic stabilizer is silicon dioxide.
5. The sterilized cyanoacrylate composition of claim 1 , wherein the composition further comprises a plasticizing agent.
6. The sterilized cyanoacrylate composition of claim 1 , wherein the composition further comprises a thickening agent.
7. The sterilized cyanoacrylate composition of claim 1 , wherein the irradiation comprises electron-beam, gamma, x-ray, or microwave irradiation.
8. The sterilized cyanoacrylate composition of claim 7 , wherein the irradiation comprises gamma irradiation.
9. The sterilized cyanoacrylate composition of claim 1 , wherein the naphthoquinone 2,3-oxide of Formula (III) comprises a vitamin K oxide.
10. The sterilized cyanoacrylate composition of claim 9 , wherein the vitamin K oxide comprises vitamin K1 oxide, vitamin K3 oxide, vitamin K4 oxide, vitamin K5 oxide, vitamin K6 oxide, or vitamin K7 oxide.
11. A kit, comprising the composition of claim 1 , a container, and instructions for using the composition in a method for closing a wound on a subject or instructions for using the composition in a method for securing a catheter inserted into the skin of a subject, wherein the container optionally comprises an applicator.
12. The kit of claim 11 , wherein the container comprises an ampoule containing the composition.
13. A sterilized cyanoacrylate composition, comprising:
about 90% to about 98% by weight of a cyanoacrylate monomer,
a free radical stabilizer,
an anionic stabilizer,
about 2% to about 10% by weight of a naphthoquinone 2,3-oxide of Formula (III)
wherein R 1 is an alkyl group or an aromatic group, and R 2 is hydrogen, an alkyl group, or an aromatic group, and
wherein the naphthoquinone 2,3-oxide is miscible with and homogenously mixed together with the cyanoacrylate monomer, wherein the composition is sterilized by ethylene oxide, irradiation, or both ethylene oxide and irradiation, and wherein the viscosity of the sterilized composition is no more than about 200 centipoise after at least two years of shelf storage.
14. The composition of claim 13 , wherein the cyanoacrylate monomer is 2-octyl cyanoacrylate, n-butyl cyanoacrylate, or mixtures thereof.
15. The sterilized cyanoacrylate composition of claim 13 , wherein the naphthoquinone 2,3-oxide of Formula (III) comprises a vitamin K oxide.
16. The sterilized cyanoacrylate composition of claim 13 , wherein the free radical stabilizer comprises about 200 ppm to about 16,000 ppm of butylated hydroxyl anisole.
17. The sterilized cyanoacrylate composition of claim 13 wherein the anionic stabilizer comprises at least 20 ppm of sulfur dioxide.
18. The sterilized cyanoacrylate composition of claim 13 , further comprising about 10 ppm to about 6000 ppm of a polymerization accelerator.
19. The sterilized cyanoacrylate composition of claim 13 , wherein the naphthoquinone 2,3-oxide of Formula (III) comprises a vitamin K oxide.
20. The sterilized cyanoacrylate composition of claim 19 , wherein the vitamin K oxide comprises vitamin K1 oxide, vitamin K3 oxide, vitamin K4 oxide, vitamin K5 oxide, vitamin K6 oxide, or vitamin K7 oxide.